Fulltext

Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT-AHF trial

Su Y 1 , Ma T 1 , Wang Z 1 , Dong B 2 , Tai C 3 , Wang H 4 Show all authors , Zhang F 5 , Yan C 5 , Chen W 1 , Xu Y 1 , Ye L 6 , Tye GJ 7 , Ong SB 8 , Zhang J 9 , Xu D 1

Affiliations 

  • 1 Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China
  • 2 Department of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
  • 3 Department of Cardiology, The Second Affiliated Hospital of Nantong University, 6 Northern Haierxiang Road, Nantong, China
  • 4 Department of Cardiology, Yangpu Hospital, Tongji University, Shanghai, 20090, China
  • 5 Department of Cardiology, Qidong People's Hospital, Qidong, Jiangsu, 226200, China
  • 6 National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
  • 7 Institute for Molecular Medicine Research (INFORMM), Universiti Sains Malaysia (USM), Penang, Malaysia
  • 8 Centre for Cardiovascular Genomics and Medicine (CCGM), Lui Che Woo Institute of Innovative Medicine, Chinese University of Hong Kong (CUHK), Hong Kong
  • 9 State Key Laboratory of Cardiovascular Disease, Heart Failure Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China
ESC Heart Fail, 2020 Dec;7(6):4465-4471.
PMID: 32945150 DOI: 10.1002/ehf2.12997

Abstract

AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction using ivabradine improves clinical outcomes in patients with AHF.

METHODS AND RESULTS: SHIFT-AHF is a prospective, multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of ivabradine when adding to standard therapy in AHF patients (SHIFT-AHF). The trial will include 674 AHF patients with left ventricular ejection fraction 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications